Kyongbo Pharmaceutical Co Ltd (214390) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyongbo Pharmaceutical Co Ltd (214390) has a cash flow conversion efficiency ratio of -0.004x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-565.17 Million ≈ $-383.01K USD) by net assets (₩146.99 Billion ≈ $99.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 214390 stock market capitalisation for the company's overall valuation and market capitalisation.
Kyongbo Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Kyongbo Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kyongbo Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyongbo Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore 214390 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MLG OZ Ltd
AU:MLG
|
0.297x |
|
Synergy Innovation Co. Ltd
KQ:048870
|
0.008x |
|
Maywufa Co Ltd
TW:1731
|
0.033x |
|
Perintis Triniti Properti PT
JK:TRIN
|
0.006x |
|
IFB Agro Industries Limited
NSE:IFBAGRO
|
-0.018x |
|
Taeyang Metal Industrial Co Ltd
KO:004105
|
-0.073x |
|
Intech Biopharm Ltd
TWO:6461
|
-0.085x |
|
Toma as
PR:TOMA
|
N/A |
Annual Cash Flow Conversion Efficiency for Kyongbo Pharmaceutical Co Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025. View Kyongbo Pharmaceutical Co Ltd (214390) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩145.74 Billion ≈ $98.76 Million |
₩7.46 Billion ≈ $5.05 Million |
0.051x | +4914.11% |
| 2024-12-31 | ₩146.15 Billion ≈ $99.05 Million |
₩149.12 Million ≈ $101.05K |
0.001x | -96.96% |
| 2023-12-31 | ₩144.38 Billion ≈ $97.85 Million |
₩4.84 Billion ≈ $3.28 Million |
0.034x | -52.39% |
| 2022-12-31 | ₩143.70 Billion ≈ $97.39 Million |
₩10.13 Billion ≈ $6.86 Million |
0.070x | -42.86% |
| 2021-12-31 | ₩145.70 Billion ≈ $98.74 Million |
₩17.97 Billion ≈ $12.18 Million |
0.123x | -7.45% |
| 2020-12-31 | ₩156.06 Billion ≈ $105.76 Million |
₩20.80 Billion ≈ $14.09 Million |
0.133x | -16.02% |
| 2019-12-31 | ₩149.16 Billion ≈ $101.09 Million |
₩23.67 Billion ≈ $16.04 Million |
0.159x | +2177.40% |
| 2018-12-31 | ₩149.01 Billion ≈ $100.98 Million |
₩-1.14 Billion ≈ $-771.31K |
-0.008x | -104.19% |
| 2017-12-31 | ₩141.51 Billion ≈ $95.90 Million |
₩25.81 Billion ≈ $17.49 Million |
0.182x | -6.84% |
| 2016-12-31 | ₩129.40 Billion ≈ $87.69 Million |
₩25.33 Billion ≈ $17.16 Million |
0.196x | +466.96% |
| 2015-12-31 | ₩122.82 Billion ≈ $83.23 Million |
₩4.24 Billion ≈ $2.87 Million |
0.035x | -85.29% |
| 2014-12-31 | ₩68.33 Billion ≈ $46.31 Million |
₩16.04 Billion ≈ $10.87 Million |
0.235x | -- |
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more